 Â |
New 2023 versions of ASCIA Action Plans for Anaphylaxis
ASCIA has developed new 2023 versions of ASCIA Action Plans for Anaphylaxis, to improve ease of use, which will be available from early June 2023. This is the first major formatting change in 20 years, since ASCIA Action Plans for Anaphylaxis were first introduced in 2003.
Read more here
|
| Â |
 |
 Â |
Registration is now open for ASCIA 2023 Conference
Registration and abstract submission is now open for the ASCIA 2023 Conference, to be held at the International Convention Centre (ICC) Sydney from Tuesday 5th to Friday 8th September 2023. This is a hybrid conference, which includes in-person or virtual attendance, and on-demand viewing of sessions for all registered delegates after the conference.
Read more here
|
| Â |
 |
 Â |
ASCIA Immunodeficiency Strategy Meeting outcomes
The ASCIA Immunodeficiency Strategy for Australia and New Zealand meeting was held on Friday 28th April, to coincide with World Primary Immunodeficiency Week 2023. We welcome feedback from ASCIA members and stakeholders on the proposed actions which were developed as a result of the meeting.
Read more here
|
| Â |
 |
 Â |
AIFA research grantsÂ
A total of 16 expressions of interest were received for Allergy and Immunology Foundation of Australasia (AIFA) grants in 2023, and eight successful applications will be announced at the ASCIA 2023 Conference in September.
To find out how you can support AIFA to provide funding for more allergy and immunology research projects in 2024, read more here
|
| Â |
 |
  |
ASCIA Progress Report – National Allergy Council projects
ASCIA is working on projects to find out how anaphylaxis and allergy training is being provided in undergraduate courses for health professionals, and staff who work in schools and children’s education/care (CEC) services. The Schools/CEC survey will commence in June 2023 here. Findings from these projects will be used to make recommendations about how anaphylaxis and allergy training should be included in courses.
Read more here
|
| Â |
 |
 Â |
ASCIA submissions to the PBAC
ASCIA has lodged two submissions on 23 May 2023 in support of products that are relevant to allergy and immunology, Tavneos® (avacopan) and Dupixent® (dupilumab), which are included on the July 2023 PBAC meeting agenda.
Read more here
|
| Â |
 |
 Â |
Recent ASCIA website updates
New ASCIA Penicillin Allergy FAQ here
Updated ASCIA IVIg Infusion Guidelines here
Updated ASCIA OIT for Food Allergy Position Paper here
Updated ASCIA Guide for Milk Substitutes in CMA here
Nucala® (mepolizumab) PBS listed for CRSwNP here
|
| Â |
 |
 Â |
ASCIA webpages listed below are regularly updated
ASCIA Submissions
Publications
Research Studies
Locate a Specialist
Allergy/Immunology Positions
Conference, Meetings and Events Calendar
|
www.allergy.org.au | contact us
The purpose of ASCIA is to advance the science and practice of allergy and clinical immunology, by promoting the highest standard of medical practice, training, education and research, to improve the health and quality of life of people with allergic diseases, immunodeficiencies and other immune diseases.
AIFA is dedicated to improving the health of people with allergy and other immune diseases by funding medical research and raising awareness. 